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Background: Neonatal herpes simplex virus (HSV) infection occurs in nearly 1/3,000 births and
can result in significant morbidity and mortality. Fever is a common reason for evaluating and/or
empirically treating for suspected HSV infection, but current recommendations are based on expert
opinion, resulting in variation in clinical practice both in terms of diagnostic testing and acyclovir
use.
Objectives/Goal: Our primary objective was to identify clinical factors associated with acyclovir
use in the management of febrile infants at our institution. Our secondary objective was to identify
HSV diagnostic testing patterns among infants who did/did not receive acyclovir.
Methods/Design: Retrospective chart review of infants 0-28 days of age who were in the inpatient
setting for fever was performed. Our primary outcome was acyclovir use on admission. Selected
co-variates including initial laboratory testing, clinical history, clinical presentation, and
demographic data were analyzed for association with acyclovir use. Infants diagnosed with
influenza or respiratory syncytial virus (RSV) at admission or discharged from the ED were
excluded.
Results: 509 neonates were included for analysis; 116 received acyclovir at initial presentation
(Table 1). When compared to febrile neonates who did not receive acyclovir, infants receiving
acyclovir were younger, more often had a positive maternal history of HSV, seizures or skin
vesicles at initial presentation, or were febrile in the ED. Age and maternal history of HSV had the

strongest association with HSV use indicating that the presence of either of these covariates will
likely frequently be associated with concomitant acyclovir administration. While the isolation of
HSV by culture remains the definitive diagnostic method and gold standard of establishing neonatal
HSV disease, HSV surface cultures/PCR did not have a significant association with acyclovir
administration in our study. No infants who received acyclovir were diagnosed with HSV
infection; one neonate who did not receive acyclovir had positive HSV testing.

Table: Acyclovir status for febrile infants 0-28 days of age who were admitted (N=509).
Factors
Acyclovir Use (n=116)
No Acyclovir (n=393)
P value
Ill appearing/septic
1 (0.9%)
3/392 (0.8%)
0.92
Age
14 (7.5,22.5)
19 (12,24)
0.0017
Female
57 (49%)
169 (43%)
0.24
Public Insurance
77 (66%)
222 (56%)
0.057
Risk Status
Abnormal Urinalysis 11/108 (10%)
50/371 (13%)
0.37
Abnormal CBC 34/114 (30%)
113/382 (30%)
0.96
Positive Maternal History of HSV 13/61 (21.3%)
8/144 (5.6%)
0.001
Non-white/Multiracial
37/108 (34%)
135/360 (38%)
0.54
Seizures
3 (2.6%)
1/391 (0.3%)
0.04
Skin Vesicles
3 (2.6%)
1/392 (0.3%)
0.04
Abnormal LFTs
11/72 (15%)
14/57 (25%)
0.19
Positive CSF HSV PCR & Surface 0/116 (0%)
1/383 (0.3%)
1.000
Viral Cultures Performed
Positive CSF HSV PCR 0/113 (0%)
1/75 (1.3%)
0.40
Surface Viral Cultures Performed 50/113 (44%)
11/383 (3%)
<0.001
Caregiver Reported Fever & Fever 66 (57%)
177 (45%)
0.02
at Presentation
LOS (days, med [IQR])
61.5 (47,83)
50 (44,63)
0.0001
Values in table presented as frequency (%) or median (IQR). Corresponding p-values for tests of
2
the differences in proportions, X , Fisher’s Exact, and Two-sample Wilcoxon rank-sum (MannWhitney) tests between No Acyclovir and Acyclovir Use cohorts are provided.

Conclusions: Acyclovir use was associated with age, maternal history of HSV, seizures, skin
vesicles, and fever. The timeliness of acyclovir administration has a direct effect on mortality as
early acyclovir use decreases mortality. By identifying these factors associated with acyclovir use,
we are able to highlight diagnostic testing patterns and in the future hope to improve judicious use
of acyclovir. Diagnostic testing rarely conforms to expert recommendations for children suspected
of neonatal HSV infection. Our findings highlight the need to establish a more standardized
approach to HSV diagnostic testing and empirical acyclovir use.

